NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3

NovoCure Ltd

2025-Q2 EPS reported -$0.67 revenue$313,799,000

Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.
4,331 active patients on TTFields globally; Optune Gio active patients up 7% YoY.
Phase 3 PANOVA-3 pancreatic cancer trial met primary endpoint; PMA submission to FDA planned Q3 2025.
PMA for brain metastases from NSCLC planned H2 2025; TRIDENT and PANOVA-4 readouts expected H1 2026.
Cash and investments $911.5M as of June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.